Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- This launch represents an important step in Roche?s personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine
- Each year 300,000 patients around the world are diagnosed with triple-negative breast cancer, an aggressive disease with limited treatment options1,2
- VENTANA PD-L1 (SP142) Assay helps identify triple-negative breast cancer patients most likely to benefit from treatment with Tecentriq plus chemotherapy